Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-03-13
2008-10-28
Henley, III, Raymond J (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07442706
ABSTRACT:
The present invention relates to methods for treating sarcopenia with a growth hormone secretagogue.
REFERENCES:
patent: 6194402 (2001-02-01), Bach et al.
patent: 6380184 (2002-04-01), Li
patent: 2002/0028838 (2002-03-01), MacLean et al.
Bach, Mark A., et al.; The Effects of MK-0677, an Oral Growth Hormone Secretagogue, in Patients With Hip Fractures. J. Am. Geriatr. Soc. 2004, 52(4), 516-523.
Chapman, Ian M., et al.; Stimulation of the Growth Hormone (GH)-Insulin-Like Growth Factor-I Axis by Daily Oral Administration of a GH Secretogogue (MK-677) in Healthy Elderly Subjects. J. Clin. Endocrinol. Metab. 1996, 81(12), 4249-4257.
Chapman, Ian M., et al.; Oral Administration of Growth Hormone (GH) Releasing Peptide-Mimetic MK-677 Stimulates the GH/Insulin-Like Growth Factor-I Axis in Selected GH-Deficient Adults. J. Clin. Endocrinol. Metab. 1997, 82(10), 2455-3463.
Doherty, Timothy J.; Physiology of Aging Invited Review: Aging and Sarcopenia. J. Appl. Physiol. 2003, 95, 1717-1727.
Goodpaster, Bert H., et al.: The Loss of Skeletal Muscle Strength, Mass, and Quality in Older Adults: The Health, Aging and Body Composition Study. J. Gerontol. Med. Sci. 2006, 61A(10), 1059-1064.
Murphy, M. G., et al.; Effect of Alendronate and MK-677 (a Growth Hormone Secretagogue), Individually and in Combination, on Markers of Bone Turnover and Bone Mineral Density in Postmenopausal Osteoporotic Women. J. Clin. Endocrinol. Metab. 2001, 83(3), 1116-1125.
Wolfe, Robert R.; The Underappreciated Role of Muscle in Health and Disease. An. J. Clin. Nutr. 2006, 84, 475-482.
Smith, Roy G.: Development of Growth Hormone Secretagogues; Endocrine Reviews (26) pp. 346-360, date not available.
Murphy, M. G. et al.: Effect of Alendronate and MK-677 (a Growth Hormone Secretagogue), Individually and in Combination, on Markers of Bone Turnover and Bone Mineral Density in Postmenopausal Osteoporotic Women; The Journal of Clinical Endocrinology & Metabolism; vol. 86 No. 3 pp. 1116-1125, date not available.
Svensson, J. et al.: Two-Month Treatment of Obese Subjects with the Oral Growth Hormone (GH) Secretagogue MK-677 Increases GH Secretion, Fat-Free Mass, and Energy Expenditure; Journal of Clinical Endocrinology and Metabolism; vol. 83 No. 2; pp. 362-369, date not available.
Bach, Mark A. et al.: The Effects of MK-0677, an Oral Growth Hormone Secretagogue, in Patients with Hip Fracture; The American Geriatrics Society; JAGS 52: pp. 516-523, 2004.
Hensley, Scott: Death of Pfizer's “Youth Pill” Illustrates Drug Makers' Woes; The Wall Street Journal; http://online.wsj.com/article—email/article—print/SB102028770668599840-1MyQjAxMDA4; pp1-6;WSJ.com, date not available.
Feldman Gale P.A.
Henley, III Raymond J
LandOfFree
Methods for treating sarcopenia with a growth hormone... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treating sarcopenia with a growth hormone..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treating sarcopenia with a growth hormone... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3998093